CDK6是NUP98融合蛋白在急性髓系白血病中的关键直接靶点
该研究通过构建可调控表达NUP98/NSD1、NUP98/JARID1A和NUP98/DDX10的小鼠模型,整合染色质占据谱与体内急性失活后的转录组谱,定义了NUP98融合蛋白的核心直接转录靶点。CDK6在鼠源和人源AML样本中高表达,CDK6缺失严重减弱NUP98融合驱动的白血病发生,且NUP98融合AML在体外和体内对CDK6药理学抑制敏感。研究提出CDK4/CDK6抑制剂作为NUP98融合AML患者的新理性治疗选择。
要点
- CDK6是NUP98融合蛋白保守的关键直接转录靶点
- CDK6缺失可严重减弱NUP98融合驱动的白血病发生
- NUP98融合AML对CDK6药理学抑制敏感,支持CDK4/CDK6抑制剂治疗
核心结论
- CDK6是NUP98融合蛋白保守且关键的直接靶点,CDK4/CDK6抑制剂可作为NUP98融合AML患者的新理性治疗选择。
研究设计与样本
- 研究构建了可调控表达NUP98/NSD1、NUP98/JARID1A和NUP98/DDX10的小鼠模型,以解析不同NUP98融合蛋白调控的转录程序。
- 研究整合了NUP98融合蛋白的染色质占据谱与体内急性融合蛋白失活后的转录组谱,以定义核心直接转录靶点。
主要发现
- CDK6在鼠源和人源AML样本中高表达。
- CDK6缺失严重减弱NUP98融合驱动的白血病发生。
- NUP98融合AML在体外和体内对药理学CDK6抑制敏感。
临床怎么用
- 对于携带NUP98融合的AML患者,可考虑将CDK4/CDK6抑制剂作为理性靶向治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fusion proteins involving Nucleoporin 98 (NUP98) are recurrently found in acute myeloid leukemia (AML) and are associated with poor prognosis. Lack of mechanistic insight into NUP98-fusion-dependent oncogenic transformation has so far precluded the development of rational targeted therapies. We reasoned that different NUP98-fusion proteins deregulate a common set of transcriptional targets that might be exploitable for therapy. To decipher transcriptional programs controlled by diverse NUP98-fusion proteins, we developed mouse models for regulatable expression of NUP98/NSD1, NUP98/JARID1A, and NUP98/DDX10. By integrating chromatin occupancy profiles of NUP98-fusion proteins with transcriptome profiling upon acute fusion protein inactivation in vivo, we defined the core set of direct transcriptional targets of NUP98-fusion proteins. Among those, CDK6 was highly expressed in murine and human AML samples. Loss of CDK6 severely attenuated NUP98-fusion-driven leukemogenesis, and NUP98-fusion AML was sensitive to pharmacologic CDK6 inhibition in vitro and in vivo. These findings identify CDK6 as a conserved, critical direct target of NUP98-fusion proteins, proposing CDK4/CDK6 inhibitors as a new rational treatment option for AML patients with NUP98-fusions.
引用
- Schmoellerl J, Barbosa IAM, Eder T, et al. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood. 2020. PMID: 32344427. doi:10.1182/blood.2019003267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。